Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hua MedicineHKSE:02552 -4.64%45 PS Ratio is 4.39 as of Aug. 19, 2026, which is 72% below its 10-year median of 15.47. GuruFocus rates HKSE:02552 with a GF Score™ of 45/100 and a GF Value™ of HK$8.79 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 950 Drug Manufacturers companies, Hua Medicine ranks worse than 70.42% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Hua Medicine's share price is HK$2.365.
Hua Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.54. Hence, Hua Medicine's PS Ratio for today is 4.39.
The historical rank and industry rank for Hua Medicine's PS Ratio or its related term are showing as below:
HKSE:02552'
s PS Ratio Range Over the Past 10 Years
Min: 3.68 Med: 15.47 Max: 247
Current: 4.38
During the past 10 years, Hua Medicine's highest PS Ratio was 247.00. The lowest was 3.68. And the median was 15.47.
HKSE:02552's PS Ratio is ranked worse than 70.42% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs HKSE:02552: 4.38
During the past 12 months, the average Revenue per Share Growth Rate of Hua Medicine was 98.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 200.20% per year.
During the past 10 years, Hua Medicine's highest 3-Year average Revenue per Share Growth Rate was 200.20% per year. The lowest was 200.20% per year. And the median was 200.20% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Hua Medicine PS Ratio Related Terms
Hua Medicine PS Ratio Historical Data
* Premium members only.
The historical data trend for Hua Medicine's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's PS Ratio distribution charts can be found below:
* The bar in red indicates where Hua Medicine's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Hua Medicine's PS Ratio for today is calculated as
Hua Medicine's Share Price of today is HK$2.365.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Hua Medicine (HKSE:02552) has a PS Ratio of 4.39 as of Aug. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hua Medicine and its competitors. This is 72% below median its historical median of 15.47. Over the past decade, Hua Medicine's PS Ratio has ranged from 3.68 to 247.00. According to the industry distribution chart, Hua Medicine ranks #669 out of 950 companies in the Drug Manufacturers industry, placing it in the top 70.4%.
Is Hua Medicine's PS Ratio too high?
Hua Medicine's current PS Ratio of 4.39 is 72% below median its 10-year median of 15.47. Over the past 10 years, this metric has ranged from a low of 3.68 to a high of 247.00. The Drug Manufacturers industry median PS Ratio is 2.33. Hua Medicine's value of 4.39 is 88.4% above this industry median. Based on the distribution chart, Hua Medicine ranks #669 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hua Medicine has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #669 out of 950 companies for PS Ratio. This places Hua Medicine in the lower half of its industry. The industry median PS Ratio is 2.33. Hua Medicine's value of 4.39 is 88.4% above this benchmark. Historically, Hua Medicine's own PS Ratio has ranged from 3.68 to 247.00 over the past decade. While the company's 10-year median is 15.47 vs. the industry median of 2.33, Hua Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current PS Ratio of 4.39 is 88.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current PS Ratio is 4.39, which is 72% below median its own 10-year median of 15.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HKSE:02552) is currently considered Possible Value Trap. The stock's GF Value™ is HK$8.79, compared to a current price of HK$2.37 — trading 73.1% below its estimated fair value. The current PS Ratio is 4.39, which is 72% below median its 10-year median of 15.47 and 88.4% above the Drug Manufacturers industry median of 2.33. Hua Medicine's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Hua Medicine (HKSE:02552), the current PS Ratio is 4.39 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HKSE:02552) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of HK$2.37 is trading 73.1% below its estimated GF Value™ of HK$8.79.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HKSE:02552:
PS Ratio: 4.39 (72% below median its 10-year median of 15.47)
GF Value™: HK$8.79 vs. price of HK$2.37 (73.1% below fair value)
Industry Position: 88.4% above the Drug Manufacturers median (#669 of 950)
No single metric tells the full story. See the HKSE:02552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
45GF Score
Get the complete analysis for HKSE:02552
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02552 has been successfully added to your 
